# Protagonist Therapeutics, Inc. (PTGX) stock price

URL: https://funkfolio.com/stock/PTGX

> Protagonist Therapeutics, Inc. (PTGX) trades at $124.67, is worth $8.14B, is priced at 26.4× earnings and scores 49/100.

---

## Protagonist Therapeutics, Inc. (PTGX)

Protagonist Therapeutics, Inc. (PTGX) is a healthcare company (biotechnology) based in the United States. The share price is $124.67, down 0.13% on the day, which values the company at $8.14B. Price as of 17 Nov 2026, 22:25 UTC, from Yahoo Finance.

### Key facts

- **Share price:** $124.67 −0.13% today
- **Market value:** $8.14B
- **P/E ratio:** 26.4× last 12 months
- **Forward P/E:** 354.8×
- **Funk Score:** 49/100
- **Against its own history:** Well above its usual price usual price $26.65
- **200-week average:** $56.21 122% above
- **Sector:** Healthcare

Figures as of 17 Nov 2026, 22:25 UTC. Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

### Protagonist Therapeutics, Inc. in more detail

PTGX trades at 26.4× its last twelve months' earnings, 354.8× next year's expected earnings, 14.7× sales. Measured against its own history, the price is 368% above what its usual multiples would imply ($26.65) — well above its usual price. It sits 122% above its 200-week average of $56.21.

Over the last five fiscal years Protagonist Therapeutics, Inc. has compounded revenue 10.0% a year. Its Funk Score is 49 out of 100 (financial strength 8.3, profitability 4.2, growth 6.5, value 0.4, each out of 10).

In its favour: Altman Z in the safe zone; More cash than debt. Worth checking: Heavy stock-based pay.

3 of the superinvestors tracked here hold PTGX, including Andrew Spokes (4.7% of the portfolio), Stanley Druckenmiller (0.6% of the portfolio), Polen Capital team (0.0% of the portfolio).

### Superinvestors holding PTGX

3 of the investors tracked here report a position in their latest 13F filing.

- [Andrew Spokes Farallon Capital Management](https://funkfolio.com/gurus/farallon) 4.73% of portfolio · $907M · added · Q3 2026
- [Stanley Druckenmiller Duquesne Family Office](https://funkfolio.com/gurus/stanley-druckenmiller) 0.59% of portfolio · $25.6M · added · Q2 2026
- [Polen Capital team Polen Capital Management](https://funkfolio.com/gurus/polen-capital) 0.03% of portfolio · $3M · trimmed · Q3 2026

### Health Care companies of similar size

- [Globus Medical GMED](https://funkfolio.com/stock/GMED)
- [Madrigal Pharmaceuticals MDGL](https://funkfolio.com/stock/MDGL)
- [Henry Schein HSIC](https://funkfolio.com/stock/HSIC)
- [Oscar Health OSCR](https://funkfolio.com/stock/OSCR)
- [TG Therapeutics TGTX](https://funkfolio.com/stock/TGTX)
- [Praxis Precision Medicines PRAX](https://funkfolio.com/stock/PRAX)
- [Twist Bioscience TWST](https://funkfolio.com/stock/TWST)
- [Krystal Biotech KRYS](https://funkfolio.com/stock/KRYS)
- [10x Genomics TXG](https://funkfolio.com/stock/TXG)
- [HealthEquity HQY](https://funkfolio.com/stock/HQY)
- [Corcept Therapeutics CORT](https://funkfolio.com/stock/CORT)
- [Rhythm Pharmaceuticals RYTM](https://funkfolio.com/stock/RYTM)

Side by side: [PTGX vs KRYS (Protagonist Therapeutics, Inc. vs Krystal Biotech)](https://funkfolio.com/compare/krys-vs-ptgx) [PTGX vs TWST (Protagonist Therapeutics, Inc. vs Twist Bioscience)](https://funkfolio.com/compare/ptgx-vs-twst) [PTGX vs PRAX (Protagonist Therapeutics, Inc. vs Praxis Precision Medicines)](https://funkfolio.com/compare/prax-vs-ptgx) [PTGX vs TXG (Protagonist Therapeutics, Inc. vs 10x Genomics)](https://funkfolio.com/compare/ptgx-vs-txg) [PTGX vs HQY (Protagonist Therapeutics, Inc. vs HealthEquity)](https://funkfolio.com/compare/hqy-vs-ptgx)

[All health care companies by market value](https://funkfolio.com/companies/sector/health-care) [Largest companies in the United States](https://funkfolio.com/companies/country/united-states) [All stocks A–Z](https://funkfolio.com/stocks)

### Protagonist Therapeutics, Inc. (PTGX): questions and answers

**What is PTGX's P/E ratio?**

Protagonist Therapeutics, Inc. trades at 26.4× its last twelve months' earnings and 354.8× next year's expected earnings.

**What is Protagonist Therapeutics, Inc.'s market cap?**

Protagonist Therapeutics, Inc. is valued at $8.14B at a share price of $124.67.

**Is PTGX overvalued or undervalued?**

Against its own history, PTGX is well above its usual price: the price is 368% above the $26.65 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

**Is PTGX above its 200-week moving average?**

Yes. PTGX is 121.8% above its 200-week average of $56.21. Long-term investors watch that line because strong companies rarely trade below it for long.

**How fast is Protagonist Therapeutics, Inc. growing?**

Over the last five fiscal years Protagonist Therapeutics, Inc.'s revenue grew 10.0% a year.

**Does PTGX pay a dividend?**

Protagonist Therapeutics, Inc. does not currently pay a regular dividend.

### Learn to read these numbers

[All stocks guides →](https://funkfolio.com/learn/stocks)

- [Altman Z-score: formula, zones and where it fails](https://funkfolio.com/learn/stocks/altman-z-score)

  The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- [Analyst price targets and ratings: what they mean](https://funkfolio.com/learn/stocks/analyst-price-targets)

  An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- [Free cash flow and FCF yield explained](https://funkfolio.com/learn/stocks/free-cash-flow)

  Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.

### Cite this page

Funkfolio, “Protagonist Therapeutics, Inc. (PTGX) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/PTGX

Underlying data: Yahoo Finance; company filings with the SEC.
